Rezolute (NASDAQ:RZLT) Receives Buy Rating from JMP Securities

JMP Securities reissued their buy rating on shares of Rezolute (NASDAQ:RZLTGet Rating) in a report published on Friday, Stock Target Advisor reports. They currently have a $8.00 price objective on the stock.

RZLT has been the subject of a number of other reports. Jefferies Financial Group began coverage on Rezolute in a research report on Monday, September 12th. They set a buy rating and a $11.00 target price for the company. Cantor Fitzgerald began coverage on Rezolute in a research report on Wednesday, June 15th. They set an overweight rating and a $9.00 target price for the company. Finally, Canaccord Genuity Group reiterated an assumes rating and set a $17.00 target price on shares of Rezolute in a research report on Tuesday, August 2nd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Rezolute has an average rating of Buy and an average price target of $15.43.

Rezolute Stock Performance

RZLT opened at $2.71 on Friday. The business has a fifty day simple moving average of $2.86 and a 200 day simple moving average of $3.13. The company has a market capitalization of $91.01 million, a PE ratio of -0.86 and a beta of 2.88. Rezolute has a 1 year low of $2.06 and a 1 year high of $9.44. The company has a debt-to-equity ratio of 0.28, a current ratio of 22.35 and a quick ratio of 22.35.

Hedge Funds Weigh In On Rezolute

A number of institutional investors have recently modified their holdings of RZLT. Maven Securities LTD acquired a new position in shares of Rezolute during the 4th quarter worth $553,000. Stonepine Capital Management LLC acquired a new position in Rezolute in the 4th quarter worth about $3,864,000. Shay Capital LLC acquired a new position in Rezolute in the 4th quarter worth about $56,000. Sender Co & Partners Inc. acquired a new position in Rezolute in the 4th quarter worth about $391,000. Finally, Provence Wealth Management Group acquired a new position in Rezolute in the 1st quarter worth about $68,000. Institutional investors and hedge funds own 73.08% of the company’s stock.

Rezolute Company Profile

(Get Rating)

Rezolute, Inc, a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

Further Reading

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.